Positive Effect Of Combined Therapy Research Articles

New techniques of magnetic therapy in sanatorium and spa treatment of patients with focal pulmonary tuberculosis

The research objective is to improve the efficiency of sanatorium and spa treatment of patients with focal pulmonary tuberculosis (FPT) in the phase of resorption and carnificaton with complex application of anti-tuberculosis drug chemotherapy, drinking mineral waters (DMW) and focused pulse magnetic therapy (FPMT). Materials and methods of the research. The study included 120 patients suffering from FPT with the first detected FPT in the phase of resorption and carnificaton without emission of Mycobacteria tuberculosis (MBT-), after a standard 2–3 month intensive chemotherapy in anti-tuberculous institutions in their place of residence. By random sampling, 3groups were formed: in the main group (MG; 42 people) the patients received complex sanatorium and spa treatment (SST), standard anti-tuberculous chemotherapy (isoniaside and pyrazinamide), DMW “Teberda”, FPMT; in the group of comparison (GC; 41people) the patients received standard SST and anti-tuberculous chemotherapy in combination with DMW Teberda; in the control group (CG; 37 people) the patients had only standard SST and anti-tuberculous chemotherapy. Results. Clinical effectiveness of complex SST with application of DMW and FPMT increases in comparison with application of only climatic- and anti-tuberculosis chemotherapy (CG) by 23.2% (p<0,05), and in the combination with drinking MW “Teberda” (GC) by 17.3% (p<0,05). Conclusion. The study proved synergistic positive effect of combined therapy (anti-tuberculosis chemotherapeutic agents, internal intake of medium-mineralized MW “Teberda”, FPMT) in FPT.

New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease

Resources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents and anticoagulants. The results of the most significant randomized clinical trials of the efficacy and safety of drugs from these classes in the treatment of chronic IHD are discussed. The results of the COMPASS study, which obtained confirmation of the positive effect of combined therapy with rivaroxaban and acetylsalicylic acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented in detail. The safety aspects of this therapy are discussed. The position of rivaroxaban in the treatment of patients with chronic IHD with sinus rhythm is presented according to the Recommendations of the European Society of Cardiology for the diagnosis and treatment of chronic IHD (2019).

Experience in the use of double broncholytic therapy in occupational practice

Introduction.Occupational chronic obstructive pulmonary disease (COPD) is one of the leading nosological forms of occupational respiratory disease. Numerous studies have shown high effectiveness of the combination of indacaterol/glycopyrronium (Ultibro®breezhaler®) on the impact on clinical and functional indicators in the treatment of COPD in General practice.The aim of the investigation the case of occupational COPD with the analysis of the dynamics of functional indicators, tolerance to physical load and evaluation of the quality of life of workers engaged in aluminum production by using combination of indacaterol/glycopyrronium.Materials and methods.The random sampling method included 20 men, workers of aluminum production, with the established diagnosis of professional COPD at the age of 40 to 60 years. The survey was conducted (Borg scale, medical Research Council scale (mMRC) and COPD Assessment Test (CAT). Functional methods of studies were conducted: spirometry, body plethysmography, electrocardiography (ECG) and the six-minute stepper test (6-MST).Results.Against the background of 8 weeks of therapy, the volume of forced exhalation for 1 minute (FEV1) increased by 14.7% and amounted to 67.90% of the due values, the forced vital capacity of the lungs (FVC) increased by 11.3% and amounted to 76.95% of the due. According to the body plethysmography (BPG) is set to decrease in residual lung volume on average by 13.4% and static hyperinflation, confirmed by the decrease in functional residual volume (FRV) of 18.8%. During the study period increased physical activity of patients. The average difference between the distance traveled in the six-minute step test before and after treatment was 58.8 m. The analysis of personal data showed that the quality of life of patients improved, the total score in the questionnaire CAT at the beginning of the study was 16.9 points, and after 8 weeks decreased by 63% and amounted to 10.7 points.Conclusions:The Results indicate a positive effect of combination therapy with indacaterol/glycopyrronium on the course and progression of occupational COPD.

Efficiency of neuromultivit in complex therapy of patients with rheumatoid arthritis associated with diabetes mellitus

To examine the dysregulation of the autonomic nervous system and manifestations of pain syndrome in patients with rheumatoid arthritis combined with diabetes mellitus and the possibility of their correction in patients who receive complex therapy including neurotropic vitamins (neuromultivitis). One hundred and forty-six patients with rheumatoid disease were examined including 59 patients with diabetes mellitus. When testing for the presence of neuropathic pain syndrome using the diagnostic questionnaire of neuropathic pain (DN4), a greater prevalence of these features was revealed, with a high correlation with the duration of rheumatoid arthritis (r=0,56) and duration of diabetes mellitus (r=0,82). A positive effect of combined therapy with neuromultivitis on the daily rhythm of arterial pressure with its normalization and correction of autonomic disorders was noted. There were a more pronounced decrease in the frequency and severity of parasympathetic and sympathetic failure, as well as an improvement in the adaptation of the peripheral vascular system to orthostatic changes. Improvement of quality of life is, to some extent, due to the more pronounced positive effect of combined therapy with neuromultivitis on such autonomic disorders as palpitations, heart rhythm disturbances, manifestations of lipotymic disorders and even panic attacks.

Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study.

At present, inhibition of cholines-terase is the treatment of choice for subjects with mild-to-moderate Alzheimer's disease (AD). Memantine, a noncompetitive antagonist at N-methyl-d-aspartate receptors, is currently used to treat subjects with moderate-to-severe AD. The goal of this multicenter, open-label pilot study was to investigate whether combination therapy with memantine added to rivastigmine is safe and beneficial in subjects with mild-to-moderate AD. Patients with a DSM-IV diagnosis of dementia of the Alzheimer's type (N = 95), who were treated with rivastigmine (6-12 mg/day) for a maximum duration of 24 weeks prior to baseline, received memantine (5-20 mg/day) in combination with rivastigmine for 12 weeks. The primary efficacy variable was the change in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score at the end of 12 weeks compared with baseline. The study was conducted between September 15, 2003, and May 27, 2004. There was a statistically significant difference between baseline and week 12 for the ADAS-cog total score, showing a positive effect of combination therapy. Combination therapy did not evidence any unexpected safety concerns and was well-tolerated by most patients. Memantine in combination with rivastigmine appears to be safe and beneficial in patients with mild-to-moderate AD. Our results need to be confirmed in a large, long-term, randomized, double-blind, placebo-controlled clinical trial.

Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature.

Although it might be premature to consider the efficacy of lithium addition in patients unresponsive to conventional antidepressant drug treatment as established, the evidence is suggestive. Besides 26 open studies, four out of six controlled investigations reported a positive effect of combined therapy administered in the indicated sequence. Three controlled studies confirmed the original observation of de Montigny et al. that improvement may occur within 48 hours. Successful lithium addition was reported in different types of depression and after pretreatment with tricyclic antidepressants, related compounds or MAO-inhibitors. Preliminary recommendations with respect to the practical use of lithium addition are made.